Drug Transporter and Cytochrome P450 mRNA Expression in Human Ocular Barriers: Implications for Ocular Drug Disposition

• DOI: 10.1124/dmd.108.021121
• Publication Date: 2008-04-15T00:54:13Z
• Authors: Tao Zhang; Cathie D. Xiang; David Gale; Samantha Carreiro; Ellen Y. Wu; Eric Y. Zhang
• Keywords: Male; Base Sequence; Haplorhini; Eye; Polymerase Chain Reaction; 3. Good health; 03 medical and health sciences; Dogs; 0302 clinical medicine; Cytochrome P-450 Enzyme System; Pharmaceutical Preparations; Animals; Humans; Female; Pharmacokinetics; RNA, Messenger; Rabbits; DNA Primers

Studies were designed to quantitatively assess the mRNA expression of 1) 10 cytochrome P450 (P450) enzymes in human cornea, iris-ciliary body (ICB), and retina/choroid relative to their levels in the liver, and of 2) 21 drug transporters in these tissues relative to their levels in human small intestine, liver, or kidney. Potential species differences in mRNA expression of PEPT1, PEPT2, and MDR1 were also assessed in these ocular tissues from rabbit, dog, monkey, and human. P450 expression was either absent or marginal in human cornea, ICB, and retina/choroid, suggesting a limited role for P450-mediated metabolism in ocular drug disposition. In contrast, among 21 key drug efflux and uptake transporters, many exhibited relative expression levels in ocular tissues comparable with those observed in small intestine, liver, or kidney. This robust ocular transporter presence strongly suggests a significant role that transporters may play in ocular barrier function and ocular pharmacokinetics. The highly expressed efflux transporter MRP1 and uptake transporters PEPT2, OCT1, OCTN1, and OCTN2 may be particularly important in absorption, distribution, and clearance of their drug substrates in the eye. Evidence of cross-species ocular transporter expression differences noted in these studies supports the conclusion that transporter expression variability, along with anatomic and physiological differences, should be taken into consideration to better understand animal ocular pharmacokinetic and pharmacodynamic data and the scalability to human for ocular drugs.